Creso Pharma


Cara Therapeutics, Inc.

CARA


Canadian symbol: CARA
US symbol: CARA

Currency in USD

Valuation Measures

Market Cap (intraday) 5955.78M
Enterprise Value 3838.63M
Trailing P/E N/A
Forward P/E 1-10.90
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)34.75
Price/Book (mrq)7.04
Enterprise Value/Revenue 330.49
Enterprise Value/EBITDA 6-8.17

Trading Information

Stock Price History

Beta (5Y Monthly) 1.70
52-Week Change 318.61%
S&P500 52-Week Change 317.60%
52 Week High 321.64
52 Week Low 38.88
50-Day Moving Average 316.38
200-Day Moving Average 315.50

Share Statistics

Avg Vol (3 month) 3437.93k
Avg Vol (10 day) 3635.4k
Shares Outstanding 549.83M
Float 41.87M
% Held by Insiders 110.47%
% Held by Institutions 168.72%
Shares Short (Dec. 30, 2020) 43.84M
Short Ratio (Dec. 30, 2020) 49.2
Short % of Float (Dec. 30, 2020) 48.73%
Short % of Shares Outstanding (Dec. 30, 2020) 47.71%
Shares Short (prior month Nov. 29, 2020) 43.85M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:2
Last Split Date 3Jan. 15, 2014

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 30, 2019
Most Recent Quarter (mrq)Sep. 29, 2020

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-374.04%

Management Effectiveness

Return on Assets (ttm)-31.29%
Return on Equity (ttm)-58.34%

Income Statement

Revenue (ttm)27.5M
Revenue Per Share (ttm)0.59
Quarterly Revenue Growth (yoy)60.20%
Gross Profit (ttm)-93.93M
EBITDA -102.68M
Net Income Avi to Common (ttm)-99.11M
Diluted EPS (ttm)-2.12
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)120.87M
Total Cash Per Share (mrq)2.43
Total Debt (mrq)3.72M
Total Debt/Equity (mrq)2.91
Current Ratio (mrq)8.00
Book Value Per Share (mrq)2.73

Cash Flow Statement

Operating Cash Flow (ttm)-118.74M
Levered Free Cash Flow (ttm)-82.86M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
CARA
Cara Therapeutics
2 months ago
CARA
Cara Therapeutics
2 months ago
CARA
Cara Therapeutics
3 months ago
CARA
Cara Therapeutics
3 months ago
CARA
Cara Therapeutics
4 months ago
CARA
Cara Therapeutics
4 months ago
CARA
Cara Therapeutics
4 months ago
CARA
Cara Therapeutics
5 months ago
CARA
Cara Therapeutics
7 months ago
CARA
Cara Therapeutics
7 months ago
CARA
Cara Therapeutics
8 months ago
CARA
Cara Therapeutics
8 months ago
CARA
Cara Therapeutics
8 months ago
CARA
Cara Therapeutics
9 months ago
CARA
Cara Therapeutics
9 months ago
CARA
Cara Therapeutics
9 months ago
CARA
Cara Therapeutics
9 months ago
CARA
Cara Therapeutics
9 months ago
CARA
Cara Therapeutics
9 months ago
CARA
Cara Therapeutics
9 months ago
CARA
Cara Therapeutics
10 months ago
CARA
Cara Therapeutics
10 months ago
CARA
Cara Therapeutics
10 months ago
CARA
Cara Therapeutics
10 months ago
CARA
Cara Therapeutics
11 months ago
CARA
Cara Therapeutics
11 months ago
CARA
Cara Therapeutics
11 months ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago

Currency in USD
Earnings EstimateCurrent Qtr. (Dec 2020)Next Qtr. (Mar 2021)Current Year (2020)Next Year (2021)
No. of Analysts7388
Avg. Estimate0.36-0.51-1.22-1.76
Low Estimate-0.73-0.63-2.31-2.51
High Estimate1.63-0.40.23-0.87
Year Ago EPS-0.61-0.62-2.49-1.22
Revenue EstimateCurrent Qtr. (Dec 2020)Next Qtr. (Mar 2021)Current Year (2020)Next Year (2021)
No. of Analysts7388
Avg. Estimate48.63M3.38M65.73M28.16M
Low Estimate4MN/A25.27MN/A
High Estimate112M10.15M134.99M47.5M
Year Ago Sales4.51M4.76M19.89M65.73M
Sales Growth (year/est)978.00%-29.00%230.50%-57.20%
Earnings History2019-12-302020-03-302020-06-292020-09-29
EPS Est.-0.66-0.62-0.67-0.6
EPS Actual-0.61-0.62-0.54-0.35
Difference0.0500.130.25
Surprise %7.60%0.00%19.40%41.70%
EPS TrendCurrent Qtr. (Dec 2020)Next Qtr. (Mar 2021)Current Year (2020)Next Year (2021)
Current Estimate0.36-0.51-1.22-1.76
7 Days Ago0.36-0.51-1.22-1.76
30 Days Ago0.35-0.56-1.23-1.78
60 Days Ago0.35-0.56-1.23-1.78
90 Days Ago-0.59-0.64-2.35-2.09
EPS RevisionsCurrent Qtr. (Dec 2020)Next Qtr. (Mar 2021)Current Year (2020)Next Year (2021)
Up Last 7 DaysN/AN/AN/AN/A
Up Last 30 Days1N/A11
Down Last 7 DaysN/AN/AN/AN/A
Down Last 30 DaysN/AN/AN/AN/A
Growth EstimatesCARAIndustrySector(s)S&P 500
Current Qtr.159.00%N/AN/AN/A
Next Qtr.17.70%N/AN/AN/A
Current Year51.00%N/AN/AN/A
Next Year-44.30%N/AN/AN/A
Next 5 Years (per annum)N/AN/AN/AN/A
Past 5 Years (per annum)N/AN/AN/AN/A


Insiders transactions are updated every hour.

Major Holders

Currency in USD
Breakdown
10.47%% of Shares Held by All Insider
68.72%% of Shares Held by Institutions
76.76%% of Float Held by Institutions
224Number of Institutions Holding Shares

Top Institutional Holders

HolderSharesDate Reported% OutValue
Blackrock Inc.3,694,949Sep. 29, 20207.41%47,018,226
Price (T.Rowe) Associates Inc3,177,992Sep. 29, 20206.38%40,439,948
RHO Capital Partners Inc2,799,058Sep. 29, 20205.62%35,618,013
Farallon Capital Management LLC2,250,000Sep. 29, 20204.52%28,631,250
Vanguard Group, Inc. (The)2,239,799Sep. 29, 20204.49%28,501,442
First Manhattan Company2,124,421Sep. 29, 20204.26%27,033,257
Carmignac Gestion1,905,680Sep. 29, 20203.82%24,249,778
Chescapmanager LLC1,314,303Sep. 29, 20202.64%16,724,505
Bank of America Corporation1,129,197Sep. 29, 20202.27%14,369,031
State Street Corporation949,533Sep. 29, 20201.91%12,082,807

Top Mutual Fund Holders

HolderSharesDate Reported% OutValue
Vanguard Total Stock Market Index Fund1,161,252Sep. 29, 20202.33%14,776,931
iShares Russell 2000 ETF992,242Dec. 30, 20201.99%15,012,621
Price (T.Rowe) Health Sciences Fund671,030Sep. 29, 20201.35%8,538,856
Vanguard Extended Market Index Fund652,613Sep. 29, 20201.31%8,304,500
ETF Managers Tr-EFTMG Alternative Harvest ETF647,082Sep. 29, 20201.30%8,234,118
Price (T.Rowe) New Horizons Fund644,829Sep. 29, 20201.29%8,205,449
Price (T.Rowe) Small-Cap Value Fund497,110Sep. 29, 20201.00%6,325,724
iShares NASDAQ Biotechnology ETF436,635Dec. 30, 20200.88%6,606,287
Price (T.Rowe) Small Cap Stock Fund414,707Sep. 29, 20200.83%5,277,146
iShares Russell 2000 Growth ETF381,528Dec. 30, 20200.77%5,772,518
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by Cara Therapeutics, Inc.


Cara Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

Cara Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

STAMFORD, Conn., Jan. 06, 2021 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Exe... Read More...
Cara Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KORSUVAâ„¢ Injection in Hemodialysis Patients with Moderate-to-Severe Pruritus

Cara Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KORSUVAâ„¢ Injection in Hemodialysis Patients with Moderate-to-Severe Pruritus

First NDA submission for Company’s lead program, KORSUVA™ Injection –NDA submission includes request for Priority Review under Breakthrough Therapy Designation for KORSUVA Injection –STAMFORD, Conn., Dec. 28, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical ... Read More...
SWK Holdings' Subsidiary, Enteris BioPharma, Receives Second Milestone Payment from Cara Therapeutics

SWK Holdings’ Subsidiary, Enteris BioPharma, Receives Second Milestone Payment from Cara Therapeutics

Second milestone payment related to the development of Oral KORSUVAâ„¢ follows initial $2.5 million milestone payment received in OctoberDALLAS, Dec. 24, 2020 -- SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that its who... Read More...
Cara Therapeutics Completes Full Enrollment in KARE Phase 2 Trial of Oral KORSUVAâ„¢ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus

Cara Therapeutics Completes Full Enrollment in KARE Phase 2 Trial of Oral KORSUVAâ„¢ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus

- Topline data expected in first half of 2021 -STAMFORD, Conn., Dec. 02, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that it has... Read More...
Cara Therapeutics Reports Third Quarter 2020 Financial Results

Cara Therapeutics Reports Third Quarter 2020 Financial Results

– Conference call today at 4:30 p.m. ET –STAMFORD, Conn., Nov. 09, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs), today announced financial results a... Read More...
Cara Therapeutics to Announce Third Quarter 2020 Financial Results on November 9, 2020

Cara Therapeutics to Announce Third Quarter 2020 Financial Results on November 9, 2020

STAMFORD, Conn., Nov. 02, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast... Read More...
SWK Holdings' Subsidiary, Enteris BioPharma, Receives Milestone Payment from Cara Therapeutics

SWK Holdings’ Subsidiary, Enteris BioPharma, Receives Milestone Payment from Cara Therapeutics

First of multiple anticipated milestone payments related to the development of Oral KORSUVAâ„¢DALLAS, Oct. 27, 2020 -- SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that its wholly-owned subsidiary, Enteris BioPharma, re... Read More...
Cara Therapeutics Announces Presentation at American Society of Nephrology Kidney Week 2020

Cara Therapeutics Announces Presentation at American Society of Nephrology Kidney Week 2020

- Results from global KALM-2 pivotal Phase 3 trial of KORSUVA™ Injection in hemodialysis patients with pruritus to be presented –- NDA submission for KORSUVA Injection on track for fourth quarter 2020 - STAMFORD, Conn., Oct. 21, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercia... Read More...
Vifor Pharma and Cara Therapeutics sign US license agreement for IV Korsuvaâ„¢* to treat dialysis patients with pruritus

Vifor Pharma and Cara Therapeutics sign US license agreement for IV Korsuvaâ„¢* to treat dialysis patients with pruritus

Vifor Pharma secures commercial rights for IV Korsuva in non-Fresenius Medical Care dialysis clinics representing approx. 66% of the market, under a profit-sharing arrangement with CaraCara will receive a USD 100 million upfront payment and an equity investment of USD 50 millionIV Korsuva aims to address a significant unmet medical need f... Read More...
Cara Therapeutics Reports Second Quarter 2020 Financial Results

Cara Therapeutics Reports Second Quarter 2020 Financial Results

– Conference call today at 4:30 p.m. ET –STAMFORD, Conn., Aug. 10, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs), today announced financial results a... Read More...
Cara Therapeutics to Present at the Canaccord Genuity 40th Annual Growth Conference

Cara Therapeutics to Present at the Canaccord Genuity 40th Annual Growth Conference

STAMFORD, Conn., Aug. 06, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Exe... Read More...
Cara Therapeutics to Announce Second Quarter 2020 Financial Results on August 10, 2020

Cara Therapeutics to Announce Second Quarter 2020 Financial Results on August 10, 2020

STAMFORD, Conn., Aug. 03, 2020 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that the Company will host a conference call and live audio... Read More...
Cara Therapeutics Expands Board of Directors with Appointment of Susan Shiff, Ph.D., M.B.A.

Cara Therapeutics Expands Board of Directors with Appointment of Susan Shiff, Ph.D., M.B.A.

STAMFORD, Conn., June 30, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced the appointment of Susan Shiff, Ph.D., M.B.A., to its Boar... Read More...
Cara Therapeutics Announces Completion of Interim Statistical Assessment for KARE Phase 2 Trial of Oral KORSUVAâ„¢ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus

Cara Therapeutics Announces Completion of Interim Statistical Assessment for KARE Phase 2 Trial of Oral KORSUVAâ„¢ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus

- Patient enrollment increased approximately 28% to maintain >80% statistical power for primary endpoint and key registration endpoint of  >4-point improvement responder analysis -- Full trial enrollment expected in fourth quarter of 2020 - STAMFORD, Conn., June 17, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical... Read More...
Cara Therapeutics to Present at the Jefferies Virtual Healthcare Conference

Cara Therapeutics to Present at the Jefferies Virtual Healthcare Conference

STAMFORD, Conn., May 27, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Exec... Read More...
Cara Therapeutics to Present at the Virtual BofA Securities 2020 Health Care Conference

Cara Therapeutics to Present at the Virtual BofA Securities 2020 Health Care Conference

STAMFORD, Conn., May 07, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Exec... Read More...
Cara Therapeutics to Announce First Quarter 2020 Financial Results on May 11, 2020

Cara Therapeutics to Announce First Quarter 2020 Financial Results on May 11, 2020

STAMFORD, Conn., May 04, 2020 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast o... Read More...
VFMCRP and Cara Therapeutics announce positive results from global KALM-2 pivotal phase-III trial of KORSUVAâ„¢ injection in haemodialysis patients with Pruritus

VFMCRP and Cara Therapeutics announce positive results from global KALM-2 pivotal phase-III trial of KORSUVAâ„¢ injection in haemodialysis patients with Pruritus

Statistically significant improvement in primary endpoint of proportion of patients with three point or greater reduction in mean worst itching intensity NRS score vs. placebo (p=0.02) Statistically significant improvement in key secondary endpoint of proportion of patients with four point or greater reduction in mean worst itching intens... Read More...
Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma Announce Positive Results From Global KALM-2 Pivotal Phase 3 Trial of KORSUVATM Injection in Hemodialysis Patients with Pruritus

Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma Announce Positive Results From Global KALM-2 Pivotal Phase 3 Trial of KORSUVATM Injection in Hemodialysis Patients with Pruritus

Statistically significant improvement in primary endpoint of proportion of patients with three point or greater reduction in mean Worst Itching Intensity NRS score vs. placebo (p=0.02) -Statistically significant improvement in key secondary endpoint of proportion of patients with four point or greater reduction in mean worst itching inten... Read More...
Cara Therapeutics to Present at the Virtual 19th Annual Needham Healthcare Conference

Cara Therapeutics to Present at the Virtual 19th Annual Needham Healthcare Conference

STAMFORD, Conn., April 08, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Ex... Read More...
Cara Therapeutics Reports Clinical Updates

Cara Therapeutics Reports Clinical Updates

- On track to report topline data for KALM-2 Phase 3 global trial of  KORSUVA™ Injection in second quarter –                   - On track to complete interim statistical analysis for ongoing Phase 2 trial of Oral KORSUVA in atopic dermatitis in second quarter - - Timeline to submit KORSUVA Injection New Drug Application to FDA in second h... Read More...
Cara Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

Cara Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

STAMFORD, Conn., Feb. 27, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced financial results and operational highlights for the fourt... Read More...
Cara Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on February 27, 2020

Cara Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on February 27, 2020

STAMFORD, Conn., Feb. 20, 2020 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast ... Read More...
Cara Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

Cara Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

STAMFORD, Conn., Jan. 08, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors, today announced a Company presentation at the 38th Annual J.P. Morgan Healthcare ... Read More...
Cara Therapeutics Announces Equity Grants to Employees Under Inducement Plan

Cara Therapeutics Announces Equity Grants to Employees Under Inducement Plan

STAMFORD, Conn., Dec. 06, 2019 -- Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Compensation Committee of Cara’s Board of Directors has approved t... Read More...
Cara Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

Cara Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

STAMFORD, Conn., Dec. 03, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors, today announced a Company presentation at the 31st Annual Piper Jaffray Healthcar... Read More...
Cara Therapeutics Announces Positive Topline Data From Phase 2 Trial of Oral KORSUVAâ„¢ in Chronic Kidney Disease Patients with Moderate-to-Severe Pruritus

Cara Therapeutics Announces Positive Topline Data From Phase 2 Trial of Oral KORSUVAâ„¢ in Chronic Kidney Disease Patients with Moderate-to-Severe Pruritus

– Met primary endpoint with statistically significant reduction in mean worst itching intensity NRS scores with 1 mg tablet strength vs. placebo after 12-week treatment period (p=0.018) –– Oral KORSUVA™ well-tolerated after 12 weeks of treatment –– Conference call today at 8:30 a.m. ET –STAMFORD, Conn., Dec. 03, 2019 -- Cara Therapeutics,... Read More...
Cara Therapeutics Announces Publication of Difelikefalin (KORSUVAâ„¢ Injection) KALMâ„¢-1 Phase 3 Trial Results in the New England Journal of Medicine

Cara Therapeutics Announces Publication of Difelikefalin (KORSUVAâ„¢ Injection) KALMâ„¢-1 Phase 3 Trial Results in the New England Journal of Medicine

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm" type="text" content="- Treatment with KORSUVA Injection resulted in statistically significant reduction in pruritus intensity and improvement in itch-related quality of life measures vs placebo for both primary and secondary endpoints -" data-... Read More...
Cara Therapeutics Reports Third Quarter 2019 Financial Results

Cara Therapeutics Reports Third Quarter 2019 Financial Results

– Conference call today at 4:30 p.m. ET –STAMFORD, Conn., Nov. 05, 2019 -- Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced financial results and operational ... Read More...
Cara Therapeutics to Announce Third Quarter 2019 Financial Results on November 5, 2019

Cara Therapeutics to Announce Third Quarter 2019 Financial Results on November 5, 2019

STAMFORD, Conn., Oct. 29, 2019 -- Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Tues... Read More...
Cara Therapeutics Announces Completion of Interim Statistical Assessment and Small Increase in Target Enrollment for KALM-2 Phase 3 Global Trial of KORSUVAâ„¢ Injection in Hemodialysis Patients with Pruritus

Cara Therapeutics Announces Completion of Interim Statistical Assessment and Small Increase in Target Enrollment for KALM-2 Phase 3 Global Trial of KORSUVAâ„¢ Injection in Hemodialysis Patients with Pruritus

- Patient enrollment increased approximately 20% to maintain >90% statistical power - - Full trial enrollment expected in fourth quarter of 2019 -STAMFORD, Conn., Oct. 14, 2019 -- Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on the treat... Read More...
Cara Therapeutics to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

Cara Therapeutics to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

STAMFORD, Conn., Sept. 26, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors, today announced a Company presentation at the 2019 Cantor Fitzgerald Global... Read More...
Cara Therapeutics Enters into Commercial License Agreement with Enteris BioPharma, Inc. for Peptelligence® Oral Formulation Technology

Cara Therapeutics Enters into Commercial License Agreement with Enteris BioPharma, Inc. for Peptelligence® Oral Formulation Technology

STAMFORD, Conn., Aug. 21, 2019 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on the treatment of pruritus by selectively targeting peripheral kappa opioid receptors, today announced that it has entered into a non-exclusive commerci... Read More...
Enteris BioPharma and Cara Therapeutics Enter into Licensing Agreement for Peptelligence® to Advance Development of Oral KORSUVA™

Enteris BioPharma and Cara Therapeutics Enter into Licensing Agreement for Peptelligence® to Advance Development of Oral KORSUVA™

Deal Showcases the Potential of Peptelligence® as the "Gold Standard" Technology for Developing Oral Formulations of Peptide-Based DrugsOral KORSUVA™ is Currently the Subject of Three Separate Phase 2 Clinical Trials for Differing Indications of PruritisBOONTON, N.J., Aug. 21, 2019 -- Enteris BioPharma, Inc., a biotechnology company devel... Read More...
Cara Therapeutics Reports Second Quarter 2019 Financial Results

Cara Therapeutics Reports Second Quarter 2019 Financial Results

– Conference call today at 4:30 p.m. ET –STAMFORD, Conn., Aug. 07, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced financial results and oper... Read More...
Cara Therapeutics to Announce Second Quarter 2019 Financial Results on August 7, 2019

Cara Therapeutics to Announce Second Quarter 2019 Financial Results on August 7, 2019

STAMFORD, Conn., July 31, 2019 -- Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Wedn... Read More...
Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

STAMFORD, Conn., July 29, 2019 -- Cara Therapeutics, Inc. (CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced the closing of its underwritten public offering of 6,325,000... Read More...
Cara Therapeutics Announces Pricing of $126.5 Million Offering of Common Stock

Cara Therapeutics Announces Pricing of $126.5 Million Offering of Common Stock

STAMFORD, Conn., July 24, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced the pricing of its underwritten public offering... Read More...
Cara Therapeutics Announces No Modifications in Trial Size for Phase 2 Trial of Oral KORSUVAâ„¢ in Chronic Kidney Disease Patients with Pruritus after Completion of Interim Statistical Assessment

Cara Therapeutics Announces No Modifications in Trial Size for Phase 2 Trial of Oral KORSUVAâ„¢ in Chronic Kidney Disease Patients with Pruritus after Completion of Interim Statistical Assessment

- Study now fully enrolled; topline data expected in 4Q 2019 -STAMFORD, Conn., July 22, 2019 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced t... Read More...
Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Initiates Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA™ for Pruritus in Patients with Atopic Dermatitis

Enteris BioPharma’s “Feasibility-to-Licensing” Partner, Cara Therapeutics, Initiates Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVAâ„¢ for Pruritus in Patients with Atopic Dermatitis

Oral KORSUVA is now the subject of three separate, ongoing Phase 2 clinical trialsBOONTON, N.J., July 11, 2019 -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies, congratulates Cara Therapeutics (CARA) on the successful initiation of its Phase 2 clinic... Read More...
Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVAâ„¢ (CR845/difelikefalin) for Pruritus in Patients with Atopic Dermatitis

Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVAâ„¢ (CR845/difelikefalin) for Pruritus in Patients with Atopic Dermatitis

STAMFORD, Conn., July 09, 2019 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced the initiation of a Phase 2 trial of Oral KORSUVA (CR845/difelikefal... Read More...
Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVAᵀᴹ (CR845/difelikefalin) for Pruritus in Patients with Primary Biliary Cholangitis (PBC)

Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVAᵀᴹ (CR845/difelikefalin) for Pruritus in Patients with Primary Biliary Cholangitis (PBC)

STAMFORD, Conn., June 26, 2019 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced the initiation of a Phase 2 trial of Oral KORSUVA (CR845/difelikefal... Read More...
Cara Therapeutics Announces Positive Results From KALM-1 Pivotal Phase 3 Trial of KORSUVAâ„¢ Injection in Hemodialysis Patients with Pruritus

Cara Therapeutics Announces Positive Results From KALM-1 Pivotal Phase 3 Trial of KORSUVAâ„¢ Injection in Hemodialysis Patients with Pruritus

- Statistically significant improvement in primary endpoint of proportion of patients with three point or greater reduction in mean worst itching intensity NRS score vs. placebo (p=0.000019) –- Statistically significant improvement in key secondary endpoint of proportion of patients with four point or greater reduction in mean worst itchi... Read More...
Cara Therapeutics to Present at the Bank of America Merrill Lynch 2019 Health Care Conference

Cara Therapeutics to Present at the Bank of America Merrill Lynch 2019 Health Care Conference

STAMFORD, Conn., May 08, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors, today announced a Company presentation at the Bank of America Merrill Lynch 2019 H... Read More...
Coming Soon.

Delayed data (1h)


Share this page